Discussing prevalence, impacts, and treatment of substance use disorders in athletes

Imagem de Miniatura
Arquivos
art_GIL_Discussing_prevalence_impacts_and_treatment_of_substance_use_2016.PDF (924.39 KB)
Citações na Scopus
25
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS LTD
Autores
GIL, Felipe
Citação
INTERNATIONAL REVIEW OF PSYCHIATRY, v.28, n.6, Special Issue, p.572-578, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The consumption of alcohol, tobacco, and other drugs has become a concern in high-performance athletes. Professional athletes are more exposed to drugs than the general population. Although some drugs are unquestionably detrimental to performance, several studies have nevertheless shown evidence of increased consumption of these substances within this sub-population. This review aimed to elucidate alcohol, tobacco, cocaine, cannabis, and opioid use among high-performance athletes, discussing the prevalence of substance use, its impacts, and alternatives to treatment in this special population. Unfortunately, no clinical trials for the treatment of substance use disorders were carried out with this specific sub-population. Therefore, the strategies adopted for the general population should be adapted to high-performance athletes. Psychological, psychosocial, psychoeducational, cognitive-behavioural, motivational interviewing approaches can be implemented. As regards pharmacological treatment, medications used in the treatment of alcohol and tobacco dependence, such as naltrexone, disulfiram, acamprosate, varenicline, bupropion, and nicotine replacement treatment can be used without problems. However, some medications used in cocaine and opioid dependence treatment, such as moldafinil and methadone, are prohibited by doping enforcement agencies. Professionals involved with athletes should be aware of the signs and symptoms of the acute effects of substances so as to enable an early identification of substance abuse problems, especially during training periods.
Palavras-chave
Athletes, alcohol, cocaine, cannabis, opioids, tobacco
URI
https://observatorio.fm.usp.br/handle/OPI/18000
Referências
  1. Ambrose Peter J, 2004, J Am Pharm Assoc (2003), V44, P501, DOI 10.1331/1544345041475698
  2. Ashton CH, 2001, BRIT J PSYCHIAT, V178, P101, DOI 10.1192/bjp.178.2.101
  3. Aveyard P, 2008, BRIT MED J, V336, P1223, DOI 10.1136/bmj.39545.852616.BE
  4. Baltieri DA, 2009, DRUG ALCOHOL DEPEN, V105, P33, DOI 10.1016/j.drugalcdep.2009.05.025
  5. Baltieri Danilo Antonio, 2004, Rev. Bras. Psiquiatr., V26, P259, DOI 10.1590/S1516-44462004000400011
  6. Barnes MJ, 2014, SPORTS MED, V44, P909, DOI 10.1007/s40279-014-0192-8
  7. Bergamaschi Mateus M, 2013, Front Psychiatry, V4, P32, DOI 10.3389/fpsyt.2013.00032
  8. Bradley K, 2014, JAMA-J AM MED ASSOC, V312, P1352, DOI 10.1001/jama.2014.10167
  9. Budney AJ, 2004, AM J PSYCHIAT, V161, P1967, DOI 10.1176/appi.ajp.161.11.1967
  10. Castaldelli-Maia JM, 2014, INT REV PSYCHIATR, V26, P515, DOI 10.3109/09540261.2014.928272
  11. Castaldelli-Maia JM, 2013, REV BRAS PSIQUIATR, V35, P338, DOI 10.1590/1516-4446-2012-0907
  12. Cota D, 2003, INT J OBESITY, V27, P289, DOI 10.1038/sj.ijo.802250
  13. da Cruz TA, 2014, INT REV PSYCHIATR, V26, P508, DOI 10.3109/09540261.2014.928271
  14. Donohue B., 2013, Journal of Clinical Sport Psychology, V7, P98
  15. Brisola Dos Santos M. B., 2016, AM J ADDICTIONS
  16. Galduroz JCF, 2005, ADDICT BEHAV, V30, P545, DOI 10.1016/j.addbeh.2004.08.004
  17. Glick ID, 2012, J CLIN PSYCHIAT, V73, P640, DOI 10.4088/JCP.11r07381
  18. Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD
  19. Haney M, 2008, PSYCHOPHARMACOLOGY, V199, P403, DOI 10.1007/s00213-008-1079-x
  20. Hoberman J, 2002, CLIN J SPORT MED, V12, P203, DOI 10.1097/01.JSM.0000015922.56340.19
  21. Kingsland Melanie, 2016, Syst Rev, V5, P12, DOI 10.1186/s13643-016-0183-y
  22. Kirkham TC, 2009, INT REV PSYCHIATR, V21, P163, DOI 10.1080/09540260902782810
  23. Laine MK, 2016, SCAND J MED SCI SPOR, V26, P284, DOI 10.1111/sms.12442
  24. Maciel Cláudia, 2004, Rev. Bras. Psiquiatr., V26, P47, DOI 10.1590/S1516-44462004000500012
  25. Millman RB, 2003, AM J ADDICTION, V12, pS48, DOI 10.1080/10550490390210100
  26. Mogensen H, 2015, HEPATOLOGY, V61, P2110, DOI 10.1002/hep.27809
  27. National Institute on Drug Abuse, 2016, NIDA RES REP SER COC
  28. National Institute on Drug Abuse, 2014, NIDA RES REP SER PRE
  29. Perry EC, 2014, CNS DRUGS, V28, P401, DOI 10.1007/s40263-014-0163-5
  30. RENAUD AM, 1986, MED SCI SPORT EXER, V18, P685
  31. Sachdeva A, 2015, J CLIN DIAGN RES, V9, pVE01, DOI [10.7860/JCDR/2015/13407.6538, 10.7860/JCDR/2015/13392.6186]
  32. Simoni-Wastila L, 2004, SUBST USE MISUSE, V39, P1, DOI 10.1081/JA-120027764
  33. Wadsworth EJK, 2006, J PSYCHOPHARMACOL, V20, P14, DOI 10.1177/0269881105056644
  34. Watten RG, 1995, SCAND J MED SCI SPOR, V5, P364

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - ODS/03